Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | LPO | P22079 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991043 | 0.85 | KMT2A (0.52) | KMT2AMEN1MAPK1ESR1LMNA | |
| SCHEMBL12126286 | 0.83 | KMT2A (0.49) | KMT2AMEN1HPGDMAPK1LPO | |
| SCHEMBL161442 | 0.81 | KMT2A (0.48) | KMT2AMEN1HPGDMAPK1LPO | |
| SCHEMBL6489303 | 0.80 | KMT2A (0.50) | KMT2AMEN1HPGDMAPK1LPO | |
| SCHEMBL10436784 | 0.79 | KMT2A (0.56) | KMT2AMEN1HPGDMAPK1CYP1A2 | |
| SCHEMBL2959354 | 0.76 | BCHE (0.38) | KMT2AMEN1MAPK1ESR2LMNA | |
| SCHEMBL29172719 | 0.76 | KMT2A (0.44) | KMT2AMEN1HPGDMAPK1CA12 | |
| SCHEMBL18007539 | 0.75 | F2 (0.58) | KMT2AMEN1HPGDLMNAGAA | |
| SCHEMBL12126289 | 0.71 | PLAU (0.47) | KMT2AMEN1HPGDMAPK1KDM4E | |
| SCHEMBL4748490 | 0.71 | KMT2A (0.52) | KMT2AMEN1MAPK1ESR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179367-B2 | Pharmaceutical compositions for treating cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-23 | — | — | US | disclosed |
| US-10793547-B2 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190240197-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-08 | — | — | US | disclosed |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2018-06-14 | — | — | US | disclosed |
| US-7767827-B2 | Pyrazole-1-carboxylate derivatives, process for the production thereof and process for the production of pyrazole derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1884512-A1 | PYRAZOLE-1-CARBOXYLIC ESTER DERIVATIVE, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING PYRAZOLE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-6642206-B2 | Useful in treating a wide variety of diseases including infections, infestations, neoplasms and autoimmune diseases | ICN PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6573248-B2 | Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| EP-1027359-A4 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-1027359-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998016186-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179367-B2 | Pharmaceutical compositions for treating cystic fibrosis | CFTR, PKD1, ABCB11 | KMT2A 4630/4885MEN1 1520/4885HPGD 483/4885 |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | KMT2A 1887/4885MEN1 548/4885HPGD 1621/4885 |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | KMT2A 1887/4885MEN1 548/4885HPGD 1621/4885 |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | CFTR, SLC26A4, TMEM109 | KMT2A 4439/4885MEN1 3338/4885HPGD 159/4885 |
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | WEE1, CYP51A1, CYP4B1 | KMT2A 1968/4885MEN1 4418/4885HPGD 526/4885 |
| US-10793547-B2 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, TMEM109 | KMT2A 4439/4885MEN1 3338/4885HPGD 159/4885 |
| US-20190240197-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | CFTR, PKD1, ABCB11 | KMT2A 4630/4885MEN1 1520/4885HPGD 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.